Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05844046 | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients(MONTBLANC) | recruiting | Phase 2 | 83 | Enrico De Toni |
| 1 |
| Jul 16, 2024 |
| clinicaltrials |
| NCT06413342 | Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 191 | Zhejiang Cancer HospitalOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06498622 | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | recruiting | Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06243393 | Sacituzumab Govitecan in Metastatic Colorectal Cancer(TROPHIT1) | recruiting | Phase 2 / Phase 3 | 80 | University Hospital HeidelbergOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05462236 | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | recruiting | Phase 2 | 120 | AUM Biosciences Pte LtdOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06491472 | Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer | recruiting | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06487429 | Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer | recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06385730 | Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)(BLESS) | recruiting | Phase 2 | 60 | Shanghai Chest HospitalOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06482801 | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT | recruiting | Phase 2 | 90 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06454448 | Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06196697 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | recruiting | Phase 2 | 50 | Harbin Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06385418 | Fluorouracil Treatment Via Colon for Colorectal Cancer | recruiting | Phase 2 | 40 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06359275 | PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients | recruiting | Phase 2 | 81 | Fudan UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06463834 | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06084897 | Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy | recruiting | Phase 2 | 120 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06455124 | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06451211 | Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer(Neo-ICEBOAT) | recruiting | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT04891016 | Toripalimab Plus FLOT in Locally Advanced Gastric Cancer | recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06415669 | A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06429839 | Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients | recruiting | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06427460 | Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) | recruiting | Phase 2 | 67 | Changhai HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06410651 | Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT06406634 | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06397222 | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC | recruiting | Phase 2 | 23 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06389422 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05228431 | Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 121 | Zhen-Hai LuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | recruiting | Phase 2 | 111 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 57 | Fujian Medical UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06371586 | Neo-Sequence 2:NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC | recruiting | Phase 2 | 67 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06111274 | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 82 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | recruiting | Phase 1 / Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341595 | Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06145074 | Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.(IMPULS) | recruiting | Phase 2 | 30 | Zealand University HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06196788 | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer(PTCA199-9) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06234007 | Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 17, 2024source: clinicaltrials